Xu Jianfeng, Zhang Ningning
Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR 72401, USA ; College of Agriculture & Technology, Arkansas State University, Jonesboro, AR 72401, USA.
Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR 72401, USA.
Pharm Bioprocess. 2014 Dec 1;2(6):499-518. doi: 10.4155/pbp.14.32.
Plant cell culture is emerging as an alternative bioproduction system for recombinant pharmaceuticals. Growing plant cells under controlled environmental conditions allows for precise control over cell growth and protein production, batch-to-batch product consistency and a production process aligned with current good manufacturing practices. With the recent US FDA approval and commercialization of the world's first plant cell-based recombinant pharmaceutical for human use, β-glucocerebrosidase for treatment of Gaucher's disease, a new era has come in which plant cell culture shows high potential to displace some established platform technologies in niche markets. This review updates the progress in plant cell culture processing technology, highlights recent commercial successes and discusses the challenges that must be overcome to make this platform commercially viable.
植物细胞培养正成为重组药物的一种替代性生物生产系统。在可控环境条件下培养植物细胞,能够精确控制细胞生长和蛋白质生产、实现批次间产品一致性,以及使生产过程符合现行良好生产规范。随着美国食品药品监督管理局(FDA)近期批准全球首个用于人类的基于植物细胞的重组药物——用于治疗戈谢病的β-葡萄糖脑苷脂酶并将其商业化,一个新时代已然来临,在这个时代,植物细胞培养在利基市场展现出取代一些成熟平台技术的巨大潜力。本综述更新了植物细胞培养加工技术的进展,突出了近期的商业成功案例,并讨论了要使该平台具备商业可行性必须克服的挑战。